Open Access

PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)

  • Authors:
    • Vera Loizzi
    • Girolamo Ranieri
    • Mariarita Laforgia
    • Cosmo   Damiano Gadaleta
    • Giulio Gargano
    • Anila Kardhashi
    • Maria De Liso
    • Emanuele Naglieri
    • Vittoria Del Vecchio
    • Ettore Cicinelli
    • Gennaro Cormio
  • View Affiliations

  • Published online on: August 6, 2020     https://doi.org/10.3892/ol.2020.11951
  • Article Number: 90
  • Copyright: © Loizzi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epithelial ovarian cancer (EOC) has a poor prognosis. Since the introduction of paclitaxel as antineoplastic agent >20 years ago, only a few phase III randomized trials have shown challenging data regarding different therapeutic options for facing its aggressive clinical course and granting active therapies to patients. Different studies have shown the utility of poly(ADP‑ribose) polymerase (PARP) inhibitors in women with EOC with or without BRCA mutations, both germline and somatic. Three PARP inhibitors, olaparib, rucaparib and niraparib, have been recently approved by the Food and Drug Administration for clinical use in EOC patients, though with different clinical indications and profiles of toxicity, while two other molecules, veliparib and talazoparib, are still under clinical investigation. The aim of the present paper is to evaluate the current status of PARP inhibitors in terms of molecular activity, pharmacodynamic properties and clinical applications.
View Figures
View References

Related Articles

Journal Cover

October-2020
Volume 20 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cicinelli E, et al: PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review). Oncol Lett 20: 90, 2020
APA
Loizzi, V., Ranieri, G., Laforgia, M., Gadaleta, C.D., Gargano, G., Kardhashi, A. ... Cormio, G. (2020). PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review). Oncology Letters, 20, 90. https://doi.org/10.3892/ol.2020.11951
MLA
Loizzi, V., Ranieri, G., Laforgia, M., Gadaleta, C. D., Gargano, G., Kardhashi, A., De Liso, M., Naglieri, E., Del Vecchio, V., Cicinelli, E., Cormio, G."PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)". Oncology Letters 20.4 (2020): 90.
Chicago
Loizzi, V., Ranieri, G., Laforgia, M., Gadaleta, C. D., Gargano, G., Kardhashi, A., De Liso, M., Naglieri, E., Del Vecchio, V., Cicinelli, E., Cormio, G."PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)". Oncology Letters 20, no. 4 (2020): 90. https://doi.org/10.3892/ol.2020.11951